Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECONDLINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY [STUDIO DI FASE 2, IN APERTO, RANDOMIZZATO VOLTO A CONFRONTARE TAS-102 RISPETTO A TOPOTECAN O AMRUBICINA IN PAZIENTI CHE NECESSITANO DI CHEMIOTERAPIA DI SECONDA LINEA PER IL CARCINOMA POLMONARE A PICCOLE CELLULE REFRATTARIO O SENSIBILE ALLA CHEMIOTERAPIA DI PRIMA LINEA A BASE DI PLATINO].

Trial Profile

AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECONDLINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY [STUDIO DI FASE 2, IN APERTO, RANDOMIZZATO VOLTO A CONFRONTARE TAS-102 RISPETTO A TOPOTECAN O AMRUBICINA IN PAZIENTI CHE NECESSITANO DI CHEMIOTERAPIA DI SECONDA LINEA PER IL CARCINOMA POLMONARE A PICCOLE CELLULE REFRATTARIO O SENSIBILE ALLA CHEMIOTERAPIA DI PRIMA LINEA A BASE DI PLATINO].

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipiracil/trifluridine (Primary) ; Amrubicin; Topotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 11 Jul 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 08 Jan 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
    • 19 Jul 2013 Planned end date (Oct 2015) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top